Yazar "Yavaş, Güler." seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim
    Öğe
    Dose rate definition in brachytherapy
    (KARE PUBL, 2019) Yavaş, Güler.
    Brachytherapy (BRT) is defined as treatment from a short distance. The word is derived from the word "brachy" that means "short" in Greek. Treatment in BRT is performed by placing the radioactive source in or near the tumor tissue. According to the report 38 of the International Commission on Radiation Units and Measurements (ICRU 38), BRI is divided into three types according to the activity of the radioactive source. Low-dose rate (LDR) implants deliver dose at the rate of 0.4-2 Gy/h, requiring treatment times of 24-144 11. LDR BRT has extensive experience with well-known efficacy and side effects. Medium-dose rate (MDR) BRT, defined as the 2-12 Gy/h range, is rarely used. High-dose rate (HDR) BRT uses dose rates in excess of 0.2 Gy/min (12 Gy/h). Although not defined in ICRU 38, there is also a very-low dose (ultra LDR: ultra-low dose rate (ULDR)) BRT of 0.01-0.3 Gy/h. Pulse dose rate (PDR) BRT is a new BRT concept that is also not defined in ICRU 38. PDR BRT combines physical advantages of LDR BRT technology with the radiobiological advantages of LDR BRT. Each dose rate in the clinic has its advantages and disadvantages. It is difficult to compare the efficacy of dose rates in the clinic because of the lack of prospective randomized studies comparing the defined dose rates with each other. In this review, we aimed to explain the advantages, disadvantages, and common clinical sites of use of different dose rates.
  • Küçük Resim
    Öğe
    The impact of imiquimod on radiation-induced lung injury: Results of an experimental study
    (BAYRAKOL MEDICAL PUBLISHER, 2019) Calik, Mustafa.; Yavaş, Güler.; Çelik, Zeliha Esin.; Yavaş, Çağdaş.; Calik, Saniye Goknil.; Sargon, Mustafa Fevzi.; Esme, Hidir.
    Aim: Radiation-induced lung injury (RILI) is a major dose-limiting factor during thoracic irradiation. Imiquimod (Imq) is a heterocyclic amine that has been shown to be effective in diseases related to inflammation and fibrosis. In this study, we aimed to evaluate the impact of Imiquimod on RILI. Material and Method: The study included 60 adult female Wistar-Albino rats (250-300 g). Rats were divided into 6 groups: Group (G) 1: control, G2: radiotherapy (RT) only, G3 and G4: 5 and 10 mg/kg Imq; G5 and G6 RT: plus 5 and 10 mg/kg Imq groups respectively. A single dose of 15 Gray (Gy) RT was given to the lungs. Imq was applied intraperitoneal. Results: The inflammation, fibrosis, and transforming growth factor (TGF)-beta scores of the study groups were significantly different at 6th and 16th week of RT (p < 0.001 for all). At the 6th week of RT, inflammation, fibrosis, and TGF-beta scores did not differ in both RT and non-RT groups. By the 16th week of RT inflammation, fibrosis, and TGF-beta scores were significantly different between G2 and G5, and G2 and G6. Electron microscopy findings supported the results of the light microscopy. Discussion: Although Imq did not improve pneumonitis phase, Imq attenuated radiation-induced lung fibrosis. These findings should be clarified with further preclinical and clinical studies.